Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 659-665

  Scherzer, T M ^a   Reddy, K R ^b   Wrba, F ^a   Hofer, H ^a   Staufer, K ^a   Steindl Munda, P ^a   Gangl, A ^a   Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatatic C virus; Hepatitis C; Hepatocellular carcinoma; Sustained virological response

Indexed keywords

ALPHAN1 INTERFERON; COBAS; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RESEARCH; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADULT; ANTIVIRAL AGENTS; AUSTRIA; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; UNITED STATES;

EID: 49649120669     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01006.x     Document Type: Article

References (41)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002 35 : S72 S78.
2. Di Bisceglie AM, Lyra AC, Schwartz M et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003 98 : 2060 2063.
3. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001 48 : 103 109.
4. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997 26 : 62S 65S.
5. Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 2007 47 : 31 36.
6. Saito I, Miyamura T, Ohbayashi A et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990 87 : 6547 6549.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
8. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
9. Ferenci P, Formann E, Laferl H et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006 44 : 275 282.
10. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
11. Formann E, Steindl-Munda P, Hofer H et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006 23 : 507 511.
12. Swain MG, Lai M, Shiffman ML et al. Sustained virologic response (SVR) resulting from treatment with peginterferon alfa-2a (40KD) (PEGASYS[R]) alone or in combination with ribavirin (COPEGUS[R]) is durable and constitutes a cure: an ongoing 5-year follow-up. Gastroenterology 2007 132 : A 741 [#444].
13. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 : 1303 1313.
14. McHutchison JG, Poynard T, Esteban-Mur R et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002 35 : 688 693.
15. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998 27 : 1394 1402.
16. Hasegawa E, Kobayashi M, Kawamura Y et al. Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res 2007 37 : 793 800.
17. Kobayashi S, Takeda T, Enomoto M et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007 27 : 186 191.
18. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006 13 : 409 414.
19. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007 45 : 579 587.
20. Iwasaki Y, Takaguchi K, Ikeda H et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004 24 : 603 610.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 293.
22. Steindl-Munda P, Ferenci P, Brunner H et al. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver Int 2003 23 : 269 275.
23. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954 7 : 462 503.
24. Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001 357 : 196 197.
25. Tokita H, Fukui H, Tanaka A et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005 20 : 752 758.
26. Akamatsu M, Yoshida H, Shiina S et al. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006 26 : 536 542.
27. Sieja KS, Everson GT. De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci 2006 51 : 600 602.
28. Tsalis K, Zacharakis E, Sapidis N, Lambrou I, Zacharakis E, Betsis D. Adrenal metastasis as first presentation of hepatocellular carcinoma. World J Surg Oncol 2005 3 : 50.
29. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged antiviral therapy with peginterferon of advanced liver disease associated with hepatitis C: Results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2007 46 (Suppl 82A (late breaker).
30. Poynard T, Schiff E, Terg R et al. Sustained virologic response with PEGinterferon-alfa2b/ ribavirin weight based dosing in previous interferon/ribavirin HCV treatment failures Week 12 virology as a predictor of SVR in the EPIC3 trials. Gastroenterology 2005 128 (Suppl. 2 A681.
31. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006 25 : 3787 3800.
32. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006 6 : 674 687.
33. Radkowski M, Gallegos-Orozco JF, Jablonska J et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005 41 : 106 114.
34. Castillo I, Pardo M, Bartolome J et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004 189 : 7 14.
35. Carreno V. Occult hepatitis C virus infection: a new form of hepatitis C. World J Gastroenterol 2006 12 : 6922 6925.
36. Pardo M, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Perez-Mota A, Carreno V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006 23 : 1153 1159.
37. Ikeda K, Marusawa H, Osaki Y et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007 146 : 649 656.
38. Tamori A, Nishiguchi S, Shiomi S et al. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 2005 100 : 1748 1753.
39. Su Q, Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol Pathol 2003 31 : 126 133.
40. Su Q, Benner A, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 1997 431 : 391 406.
41. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001 39 : 66 73.